MoonLake Immunotherapeutics
Announces Proposed Underwritten
Public Offering
ZUG, Switzerland, June 26, 2023 – MoonLake Immunotherapeutics
(NASDAQ:MLTX) (“MoonLake”), a clinical-stage biotechnology company
focused on creating next-level therapies for inflammatory diseases,
today announced that it has commenced an underwritten public
offering of $250 million of its Class A ordinary shares and, in
lieu of Class A ordinary shares to certain investors that so
choose, pre-funded warrants to purchase Class A ordinary shares. In
addition, MoonLake is expected to grant the underwriters of the
offering an option for a period of 30 days to purchase up to an
additional $37.5 million of its Class A ordinary shares at the
public offering price, less the underwriting discounts and
commissions. The proposed public offering is subject to market and
other conditions, and there can be no assurance as to whether or
when the offering may be completed or as to the actual size or
terms of the offering. All of the securities to be sold in the
offering are being offered by MoonLake.
MoonLake intends to use the net proceeds from this offering
together with its existing cash, cash equivalents and marketable
securities, to fund the ongoing advancement of Sonelokimab and for
general corporate purposes.
SVB Securities, Guggenheim Securities, Cantor and LifeSci
Capital are acting as joint bookrunning managers for the
offering.
A shelf registration statement relating to these securities has
been filed with the Securities and Exchange Commission (“SEC”) and
became effective on May 9, 2023. The offering is being made only by
means of a prospectus, including a prospectus supplement, forming a
part of an effective registration statement. A preliminary
prospectus supplement and accompanying prospectus relating to the
offering have been filed with the SEC and are available on the
SEC’s website, located at www.sec.gov. Prospective investors should
read the preliminary prospectus supplement and the accompanying
prospectus and other documents MoonLake has filed with the SEC for
more complete information about MoonLake and the offering.
Electronic copies of the preliminary prospectus supplement and the
accompanying prospectus related to the offering may also be
obtained by contacting SVB Securities, Attention: Syndicate
Department, 53 State Street, 40th Floor, Boston, MA 02109, or by
telephone at (800) 808-7525, ext. 6105, or by email at
syndicate@svbsecurities.com; Guggenheim Securities, LLC, Attention:
Equity Syndicate Department, 330 Madison Avenue, New York, NY10017,
or by telephone at 212 518-9544, or by email at
GSEquityProspectusDelivery@guggenheimpartners.com; Cantor
Fitzgerald & Co., 499 Park Avenue, 4th Floor, New York, New
York 10022, Attn: Capital Markets Department, or by email at
prospectus@cantor.com; LifeSci Capital LLC,
Attention: Syndicate Prospectus Department, 250 West 55th
Street, 34th Floor, New York, NY 10019, by email
at compliance@lifescicapital.com or by telephone at (646)
876-5059.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation, or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About MoonLake
Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage
biopharmaceutical company unlocking the potential of Sonelokimab, a
novel investigational Nanobody® for the treatment of inflammatory
disease, to revolutionize outcomes for patients. Sonelokimab
inhibits IL-17A and IL-17F by inhibiting the IL-17A/A, IL-17A/F,
and IL-17F/F dimers that drive inflammation. The company’s focus is
on inflammatory diseases with a major unmet need, including
hidradenitis suppurativa and psoriatic arthritis – conditions
affecting millions of people worldwide with a large need for
improved treatment options. MoonLake was founded in 2021 and is
headquartered in Zug, Switzerland.
Forward-Looking Statements
This press release contains certain “forward-looking statements”
within the meaning of the U.S. Private Securities Litigation Reform
Act of 1995. Forward-looking statements include, but are not
limited to, statements regarding MoonLake’s expectations regarding
the proposed offering and the anticipated use of the net proceeds
of the offering. In addition, any statements that refer to
projections, forecasts, or other characterizations of future events
or circumstances, including any underlying assumptions, are
forward- looking statements. The words “anticipate,” “believe,”
“continue,” “could,” “estimate,” “expect,” “intend,” “may,”
“might,” “plan,” “possible,” “potential,” “predict,” “project,”
“should,” “would” and similar expressions may identify
forward-looking statements, but the absence of these words does not
mean that statement is not forward looking.
Forward-looking statements are based on current expectations and
assumptions that, while considered reasonable by MoonLake and its
management, as the case may be, are inherently uncertain. New risks
and uncertainties may emerge from time to time, and it is not
possible to predict all risks and uncertainties. Actual results
could differ materially from those anticipated in such
forward-looking statements as a result of various risks and
uncertainties, which include, without limitation, the risk that the
offering will not be consummated; the impact of general economic,
health, industrial or political conditions in the United States or
internationally; and other risks and uncertainties identified in
MoonLake’s Annual Report on Form 10-K for the year ended December
31, 2022 and other subsequent disclosure documents filed with the
SEC.
Nothing in this press release should be regarded as a
representation by any person that the forward-looking statements
set forth herein will be achieved or that any of the contemplated
results of such forward-looking statements will be achieved. You
should not place undue reliance on forward-looking statements in
this press release, which speak only as of the date they are made
and are qualified in their entirety by reference to the cautionary
statements herein. MoonLake does not undertake or accept any duty
to release publicly any updates or revisions to any forward-looking
statements to reflect any change in its expectations or in the
events, conditions or circumstances on which any such statement is
based.
MoonLake Immunotherapeutics InvestorsMatthias
Bodenstedt, CFOir@moonlaketx.com
MoonLake Immunotherapeutics MediaPatricia
Sousa, Director Corporate Affairsmedia@moonlaketx.com
Consilium Strategic CommunicationsTel: +44 (0)
20 3709 5700MoonLake@consilium-comms.comMary-Jane Elliott, Ashley
Tapp
MoonLake Immunotherapeut... (NASDAQ:MLTX)
Historical Stock Chart
From Apr 2024 to May 2024
MoonLake Immunotherapeut... (NASDAQ:MLTX)
Historical Stock Chart
From May 2023 to May 2024